Effects of L-Ornithine L-Aspartate on the Physical Performance with Experimental Non-Alcoholic Fatty Liver Disease
https://doi.org/10.33647/2074-5982-16-3-77-80
Abstract
In the present study, we evaluated the effects of L-ornithine L-aspartate on the physical performance of C57BL/6 mice with experimental non-alcoholic fatty liver disease (NAFLD) induced by a high-caloric “western” diet combined with intraperitoneal carbon tetrachloride injections. Using the forced swim test and triple weight-loaded exhaustive swim test, this model of NAFLD was shown to cause a significant impairment of physical performance and a decrease in physical recovery. L-ornithine L-aspartate was found to significantly improve physical performance and benefit post-exercise recovery in mice with NAFLD.
About the Authors
V. A. Prikhodko
Saint Petersburg State Chemical Pharmaceutical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Veronika A. Prikhodko
197376, Saint Petersburg, Professora Popova str., 14
M. A. Poveryaeva
Saint Petersburg State Chemical Pharmaceutical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Marina A. Poveryaeva
197376, Saint Petersburg, Professora Popova str., 14
Yu. I. Sysoev
Saint Petersburg State Chemical Pharmaceutical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Yuriy I. Sysoev, Cand. Sci. (Biol.)
197376, Saint Petersburg, Professora Popova str., 14
E. B. Shustov
Saint Petersburg State Chemical Pharmaceutical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Evgeniy B. Shustov, Dr. Sci. (Med.), Prof.
197376, Saint Petersburg, Professora Popova str., 14
A. V. Bunyat
Saint Petersburg State Chemical Pharmaceutical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Anna V. Bunyat
197376, Saint Petersburg, Professora Popova str., 14
References
1. Dudarenko S.V., Kovalenko A.L., Prokopenko S.M., Belogurova E.V. Primenenie remaksola v terapii metabolicheskogo sindroma u patsientov s nealkogol’nym steatogepatitom i sakharnym diabetom 2 tipa [The use of remaxol in the treatment of metabolic syndrome in patients with nonalcoholic steatohepatitis and diabetes mellitus 2 type]. Eksperimental’naia i klinicheskaia gastroenterologiia [Experimental & clinical gastroenterology]. 2016;130(6):89–94. (In Russian).
2. Karkischenko N.N., Karkischenko V.N., Shustov E.B., Berzin I.A., Kapanadze G.D., Fokin Yu.V., et al. Biomeditsinskoe (doklinicheskoe) izuchenie lekarstvennykh sredstv, vliyayushchikh na fizicheskuyu rabotosposobnost’: Metod. rekom. [Biomedical (preclinical) studies of drugs modulating physical performance. Мethodological recommendations]. Moscow: Federal Medical and Biological Agency Publ., 2017. 134 p. (In Russian).
3. Moretti R., Caruso P., Gazzin S. Non-alcoholic fatty liver disease and neurological defects. Ann. Hepatol. 2019;18(4):563–570. DOI: 10.1016/j.aohep.2019.04.007.
4. Tsuchida T., Lee Y.A., Fujiwara N., et al. A simple dietand chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J. Hepatol. 2018;69(2):385–395. DOI: 10.1016/j.jhep.2018.03.011.
Review
For citations:
Prikhodko V.A., Poveryaeva M.A., Sysoev Yu.I., Shustov E.B., Bunyat A.V. Effects of L-Ornithine L-Aspartate on the Physical Performance with Experimental Non-Alcoholic Fatty Liver Disease. Journal Biomed. 2020;16(3):77-80. (In Russ.) https://doi.org/10.33647/2074-5982-16-3-77-80
Views:
564
Email this article 
